H5N1 Flu Vaccine Proven Safe
H5S1 Flu Vaccine Proven Safe
Preliminary results from a clinical trial of Sanofi Pasteur's (Lyon, France, www.sanofi.com) H5N1 prepandemic influenza vaccine indicate the vaccine is safe and well-tolerated in 300 healthy volunteers. This study is the first trial of an H5N1 prepandemic influenza vaccine candidate that compared vaccines with and without adjuvants.
The 30 microgram-dose vaccine (with adjuvant) is given in two doses, but the company also noted that immune responses were detected in several volunteers who received smaller doses. Follow-up studies still under development will be performed using a scaled-up production method that will mimic the manufacturing scale that would be used during a true pandemic.
-Kaylynn Chiarello-Ebner
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Meeting Secondary Packaging Challenges of Innovative Delivery Systems for Biologics
February 6th 2025Rapid market growth in biologics is helping the packaging market expand as well, but the complex nature of biologics and the desire for personalized therapies present unique hurdles to make packaging solutions cost-effective and safe for patients.
